{"id":"tace-camrelizumab-apatinib-mesylate","safety":{"commonSideEffects":[{"rate":null,"effect":"Hepatic dysfunction / elevated transaminases"},{"rate":null,"effect":"Immune-related adverse events (irAEs)"},{"rate":null,"effect":"Hypertension"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Hand-foot skin reaction"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"TACE is a locoregional procedure that embolizes hepatic arteries supplying tumors while delivering chemotherapy directly to the lesion. Camrelizumab blocks PD-1 on T cells, releasing immune checkpoint inhibition to enhance anti-tumor immunity. Apatinib mesylate inhibits VEGFR and other receptor tyrosine kinases to suppress tumor angiogenesis and growth. The combination aims to synergistically improve outcomes in hepatocellular carcinoma by combining locoregional therapy, immunotherapy, and anti-angiogenic therapy.","oneSentence":"This combination therapy uses transarterial chemoembolization (TACE) to deliver chemotherapy directly to liver tumors, combined with camrelizumab (a PD-1 inhibitor) to enhance immune response and apatinib mesylate (a tyrosine kinase inhibitor) to block angiogenesis.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:37:22.311Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hepatocellular carcinoma (HCC), unresectable or advanced stage"}]},"trialDetails":[{"nctId":"NCT07314372","phase":"PHASE2","title":"FAD Subtype-Guided Combination Therapy for Unresectable Hepatocellular Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","startDate":"2026-02-01","conditions":"Unresectable Hepatocellular Carcinoma (HCC), Hepatocellular Carcinoma (HCC), Liver Cancer Adult","enrollment":86},{"nctId":"NCT07334483","phase":"PHASE2","title":"A Study of Yttrium [90Y] Microsphere Injection in Combination With Targeted Immunotherapy in the Treatment of HCC","status":"RECRUITING","sponsor":"GrandPharma (China) Co., Ltd.","startDate":"2025-08-22","conditions":"HCC","enrollment":120},{"nctId":"NCT07309419","phase":"PHASE2, PHASE3","title":"A Phase III Randomized Study of TACE Plus an Oral Triple-Agent Cocktail Versus TACE Plus First-Line Targeted Immunotherapy in Unresectable Hepatocellular Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Zhongshan Hospital","startDate":"2025-12-22","conditions":"Hepatocellular Carcinoma","enrollment":222},{"nctId":"NCT05320692","phase":"PHASE3","title":"A Study of TACE Combined With Camrelizumab Plus Rivoceranib (Apatinib) in Patients With Incurable Hepatocellular Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2022-08-09","conditions":"Hepatocellular Carcinoma","enrollment":423},{"nctId":"NCT07157969","phase":"PHASE2","title":"ICIs and Anti-VEGF Antibody/TKIs With or Without Interventional Therapy for Advanced HCC","status":"RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2025-02-19","conditions":"HCC - Hepatocellular Carcinoma","enrollment":300},{"nctId":"NCT07156617","phase":"","title":"A Study on the Heterogeneity of Efficacy of Interventional Therapy Combined With Systemic Therapy for Liver Cancer Based on Multi-center Real-world Data","status":"NOT_YET_RECRUITING","sponsor":"Xuhua Duan","startDate":"2025-10-01","conditions":"Hepatocellular Carcinoma (HCC)","enrollment":2000},{"nctId":"NCT07154082","phase":"PHASE2","title":"Apatinib Mesylate and Camrelizumab Combined With TACE as Neoadjuvant Therapy for Hepatocellular Carcinoma","status":"RECRUITING","sponsor":"Wei Zhang","startDate":"2025-12-30","conditions":"Hepatocellular Carcinoma (HCC)","enrollment":27},{"nctId":"NCT04521153","phase":"PHASE2, PHASE3","title":"Camrelizumab Combined With Apatinib Mesylate for Perioperative Treatment of Resectable Hepatocellular Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Shanghai Zhongshan Hospital","startDate":"2021-03-25","conditions":"Hepatocellular Carcinoma, Immunotherapy, Molecular Targeted Therapy","enrollment":294},{"nctId":"NCT05613478","phase":"PHASE3","title":"Camrelizumab Combined With Apatinib Mesylate and TACE in the Perioperative Treatment of Hepatocellular Carcinoma","status":"RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2023-01-31","conditions":"Hepatocellular Carcinoma, Immunotherapy, Preoperative","enrollment":130},{"nctId":"NCT06485466","phase":"PHASE3","title":"TACE Plus Camrelizumab and Apatinib for Unresectable Hepatocellular Carcinoma","status":"RECRUITING","sponsor":"Guohui Xu","startDate":"2024-07-01","conditions":"Unresectable Hepatocellular Carcinoma, Transarterial Chemoembolization, Camrelizumab","enrollment":101},{"nctId":"NCT05717738","phase":"","title":"Combined TACE, TKI/Anti-VEGF and ICIs as Conversion Therapy for Advanced Hepatocellular Carcinoma","status":"RECRUITING","sponsor":"Tongji Hospital","startDate":"2022-01-20","conditions":"Hepatocellular Carcinoma Non-resectable","enrollment":300},{"nctId":"NCT06261138","phase":"","title":"Survival Analysis: TACE vs. Combination Therapy in HCC","status":"COMPLETED","sponsor":"Zhejiang University","startDate":"2019-02-01","conditions":"Hepatocellular Carcinoma","enrollment":279},{"nctId":"NCT06205732","phase":"","title":"A Retrospective Study on the Treatment of Intermediate and Advanced Liver Cancer.","status":"UNKNOWN","sponsor":"Qianfoshan Hospital","startDate":"2024-01-01","conditions":"Carcinoma, Hepatocellular","enrollment":100},{"nctId":"NCT04559607","phase":"NA","title":"TACE Combined With Camrelizumab and Apatinib in Intermediate and Advanced Hepatocelluar Carcinoma","status":"UNKNOWN","sponsor":"Zhongda Hospital","startDate":"2020-09-11","conditions":"Hepatocellular Carcinoma","enrollment":188},{"nctId":"NCT05332496","phase":"","title":"TACE in Combination With PD-1/PD-L1 Inhibitors and Molecular Target Therapies for Intermediate HCC","status":"UNKNOWN","sponsor":"Zhongda Hospital","startDate":"2022-12-28","conditions":"Hepatocellular Carcinoma","enrollment":220},{"nctId":"NCT05332821","phase":"","title":"TACE in Combination With PD-1/PD-L1 Inhibitors and Molecular Target Therapies for Advanced HCC","status":"UNKNOWN","sponsor":"Zhongda Hospital","startDate":"2022-12-28","conditions":"Hepatocellular Carcinoma","enrollment":474},{"nctId":"NCT05550025","phase":"PHASE2","title":"TACE Combined With Camrelizumab and Apatinib in the Treatment of Advanced Liver Cancer","status":"UNKNOWN","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2021-12-17","conditions":"Hepatocellular Carcinoma","enrollment":26},{"nctId":"NCT05535998","phase":"","title":"TACE-HAIC Combined With TKIs and Immunotherapy Versus TACE Alone for Hepatocellular Carcinoma With PVTT","status":"COMPLETED","sponsor":"Yunfei Yuan","startDate":"2021-01-01","conditions":"Hepatocellular Carcinoma","enrollment":743},{"nctId":"NCT04947956","phase":"","title":"Camrelizumab in Patients With Unresectable Hepatocellular Carcinoma","status":"UNKNOWN","sponsor":"Shanghai Zhongshan Hospital","startDate":"2021-09-01","conditions":"Unresectable Hepatocellular Carcinoma","enrollment":1000},{"nctId":"NCT04479527","phase":"PHASE2","title":"Evaluation Effectiveness and Safety of (cTACE or DEB-TACE + FOLFOX Regimen HAIC) Combined With Camrelizumab and Apatinib Mesylas in the Treatment of Advanced Hepatocellular Carcinoma","status":"UNKNOWN","sponsor":"Peking University Cancer Hospital & Institute","startDate":"2021-04","conditions":"Hepatocellular Carcinoma","enrollment":34}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":8011,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"TACE+Camrelizumab+Apatinib mesylate","genericName":"TACE+Camrelizumab+Apatinib mesylate","companyName":"Jiangsu HengRui Medicine Co., Ltd.","companyId":"jiangsu-hengrui-medicine-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination therapy uses transarterial chemoembolization (TACE) to deliver chemotherapy directly to liver tumors, combined with camrelizumab (a PD-1 inhibitor) to enhance immune response and apatinib mesylate (a tyrosine kinase inhibitor) to block angiogenesis. Used for Hepatocellular carcinoma (HCC), unresectable or advanced stage.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}